What is Theraclone Sciences?
Theraclone Sciences is at the forefront of developing novel therapeutics by rapidly identifying rare human monoclonal antibodies. Their expertise lies in creating treatments for infections and diseases, leveraging over a decade of experience in screening technology for therapeutic product development. The company has demonstrated its innovative capabilities by licensing its HIV broadly neutralizing fully-human antibodies to Gilead for an HIV-cure regimen and its platform technology to OncoResponse for oncology applications. This strategic approach targets clients within the pharmaceutical and biotechnology sectors, positioning Theraclone Sciences as a key player in the life sciences innovation ecosystem.
How much funding has Theraclone Sciences raised?
Theraclone Sciences has raised a total of $35.5M across 4 funding rounds:
Series A
$2M
Series B
$29M
Unspecified
$1.5M
Private Equity
$3.1M
Series A (2004): $2M, investors not publicly disclosed
Series B (2007): $29M led by Amgen Business Development, MPM Capital, HealthCare Ventures, Canaan Partners, ARCH Venture Partners, and Alexandria Real Estate Equities
Unspecified (2010): $1.5M supported by Amgen Business Development, MPM Capital, ARCH Venture Partners, Alexandria Real Estate Equities, Healthcare Ventures, and Canaan Partners
Private Equity (2015): $3.1M, investors not publicly disclosed
Key Investors in Theraclone Sciences
Amgen Business Development
Amgen Oncology is dedicated to transforming cancer treatment through innovative therapies and a commitment to patient care. With over 40 years of experience, the company focuses on delivering high-quality biosimilar medicines to enhance treatment options and promote a sustainable healthcare system.
MPM Capital
MPM BioImpact manages early-stage venture funds, private/public impact funds and a public equities fund. We convert science into therapeutics to reach the patients that need them most.
ARCH Venture Partners
ARCH Venture Partners is a leading earlystage venture capital firm that creates and invests in life sciences and advanced technology companies, often cofounding startups with scientists and entrepreneurs to commercialize innovations from universities, corporate R&D groups, and national laboratories.
What's next for Theraclone Sciences?
With significant enterprise-level funding and a recent strategic investment, Theraclone Sciences is well-positioned for accelerated growth and expanded research and development initiatives. The company's established track record of licensing its proprietary technologies to major industry players suggests a continued focus on strategic partnerships and pipeline advancement. Future endeavors will likely involve further validation of their antibody discovery platform and the progression of licensed therapies through clinical development, aiming to address critical unmet needs in infectious diseases and oncology. This sustained financial backing provides the necessary runway for Theraclone Sciences to solidify its market position and pursue groundbreaking therapeutic solutions.
See full Theraclone Sciences company page
